Effect of SARS-CoV-2 proteins on vascular permeability

Rossana Rauti1†, Meishar Shahoha2,3†, Yael Leichtmann-Bardoogo1†, Rami Nasser4, Eyal Paz2,3, Rina Tamir1, Victoria Miller1, Tal Babich1,2, Kfir Shaked1,2, Avner Ehrlich5, Konstantinos Ioannidis2, Yaakov Nahmias5, Roded Sharan4, Uri Ashery2,3,6, Ben Meir Maoz1,3,6*

1Department of Biomedical Engineering, Tel Aviv University, Tel Aviv, Israel; 2School of Neurobiology, Biochemistry and Biophysics, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel; 3Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel; 4Blavatnik School of Computer Science, Tel Aviv University, Tel Aviv, Israel; 5Grass Center for Bioengineering, The Hebrew University of Jerusalem, Jerusalem, Israel; 6The Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv, Israel

Abstract  Severe acute respiratory syndrome (SARS)-CoV-2 infection leads to severe disease associated with cytokine storm, vascular dysfunction, coagulation, and progressive lung damage. It affects several vital organs, seemingly through a pathological effect on endothelial cells. The SARS-CoV-2 genome encodes 29 proteins, whose contribution to the disease manifestations, and especially endothelial complications, is unknown. We cloned and expressed 26 of these proteins in human cells and characterized the endothelial response to overexpression of each, individually. Whereas most proteins induced significant changes in endothelial permeability, nsp2, nsp5_c145a (catalytic dead mutant of nsp5), and nsp7 also reduced CD31, and increased von Willebrand factor expression and IL-6, suggesting endothelial dysfunction. Using propagation-based analysis of a protein–protein interaction (PPI) network, we predicted the endothelial proteins affected by the viral proteins that potentially mediate these effects. We further applied our PPI model to identify the role of each SARS-CoV-2 protein in other tissues affected by coronavirus disease (COVID-19). While validating the PPI network model, we found that the tight junction (TJ) proteins cadherin-5, ZO-1, and β-catenin are affected by nsp2, nsp5_c145a, and nsp7 consistent with the model prediction. Overall, this work identifies the SARS-CoV-2 proteins that might be most detrimental in terms of endothelial dysfunction, thereby shedding light on vascular aspects of COVID-19.

Introduction  Coronavirus disease (COVID-19) caused by the 2019 novel coronavirus (2019-nCoV/SARS-CoV-2) led to a global pandemic in 2020. By late September 2021, coronavirus had infected more than 220 million people worldwide, causing over 4.5 million deaths. After the initial phase of the viral infection, ~30% of patients hospitalized with COVID-19 develop severe disease with progressive lung damage, known as severe acute respiratory syndrome (SARS), and a severe immune response. Interestingly, additional pathologies have been observed, such as hypoxemia and cytokine storm which, in some cases, lead to heart and kidney failure, and neurological symptoms. Recent observations suggest that these pathologies are mainly due to increased coagulation and vascular dysfunction (Lee et al., 2021; Libby and Lüscher, 2020; Siddiqi et al., 2020). It is currently believed that in addition to being a respiratory disease, COVID-19 might also be a ‘vascular disease’ (Lee et al., 2021), as it may result in a leaky vascular barrier and increased expression of von Willebrand factor (VWF) (Siddiqi et al.,...
2020), responsible for increased coagulation, cytokine release, and inflammation (Siddiqi et al., 2020; Teuwen et al., 2020; Aid et al., 2020; Potus et al., 2020; Wazny et al., 2020; Pum et al., 2021; Barbosa et al., 2021; Lin et al., 2020; Matarese et al., 2020; Xiao et al., 2020). Recent studies suggest that the main mechanism disrupting the endothelial barrier occurs in several stages: First, a direct effect on the endothelial cells that causes an immune response of the vascular endothelium (endotheliitis) and endothelial dysfunction. Second, lysis and death of the endothelial cells Teuwen et al., 2020; Xiao et al., 2020 followed by sequestration of human angiotensin I-converting enzyme 2 (hACE2) by viral spike proteins that activate the kallikrein–bradykinin and renin–angiotensin pathways, increasing vascular permeability (Teuwen et al., 2020; Varga et al., 2020). Last, overreaction of the immune system, during which a combination of neutrophils and immune cells producing reactive oxygen species, inflammatory cytokines (e.g., interleukin [IL]-1β, IL-6, and tumor necrosis factor), and vasoactive molecules (e.g., thrombin, histamine, thromboxane A2, and vascular endothelial growth factor), and the deposition of hyaluronic acid lead to disruption of endothelial junctions, increased vascular permeability, and leakage and coagulation (Libby and Lüscher, 2020; Teuwen et al., 2020; Varga et al., 2020). Of great interest is the effect on the brain's vascular system. Cerebrovascular effects have been suggested to be among the long-lasting effects of COVID-19. Indeed, the susceptibility of brain endothelial cells to direct SARS-CoV-2 infection was found to increase due to increased expression of hACE2 in a blood flow-dependent manner, leading to a unique gene expression process that might contribute to the cerebrovascular effects of the virus (Pober and Sessa, 2007).

While many studies point out the importance of the vascular system in COVID-19 (Kaneko et al., 2021; Jung et al., 2020b; Nägele et al., 2020), only a few (Pons et al., 2020; Chioh et al., 2020; Nascimento Conde et al., 2020; Buzhdygan et al., 2020) have looked at the direct vascular response to the virus. Most of those reports stem from either clinical observations, or in vitro studies or in vivo

---

**Figure 1.** Effect of severe acute respiratory syndrome (SARS)-CoV-2 proteins on endothelial cells. (a) Sketch representing the main organs affected by SARS-CoV-2; (b) structure and gene composition of SARS-CoV-2.
studies in which animals/cells were transfected with the SARS-CoV-2 virus and their systemic cellular response assessed, without pinpointing the specific viral protein(s) causing the observed changes. SARS-CoV-2 is an enveloped virus with a positive-sense, single-stranded RNA genome of ~30 kb, encoding 29 proteins (Figure 1). These proteins can be classified as: structural proteins: S (spike proteins), E (envelope proteins), M (membrane proteins), N (nucleocapsid protein and viral RNA); nonstructural proteins: nsp1–16; open reading frame accessory proteins: orf3–10 (Kim et al., 2020; Hu et al., 2021). Table 1 summarizes the known effects of specific SARS-CoV-2 proteins (Gordon et al., 2020; Peng et al., 2020b; Procko, 2020; Cornillez-Ty et al., 2009; Romano et al., 2020; Hillen et al., 2020; Chi et al., 2003). The functionality of some of these is still unknown. Moreover, a considerable knowledge gap still exists regarding molecular mechanisms, especially the protein–protein interaction (PPI) pathways (Cowen et al., 2017), leading to tissue dysfunction.

To tackle these challenges, we cultured human umbilical vein endothelial cells (HUVECs) and systematically transduced them with lentiviral particles encoding 26 out of the 29 viral proteins, separately. The three remaining genes were not included in this study purely for technical reasons. We then examined their effects on HUVEC monolayer permeability and the expression of factors involved in vascular permeability and coagulation. The results were analyzed in the context of virus–host and host–host PPI networks. By combining the insights from the experimental and computational results, we generated a model that explains how each of the 26 proteins of SARS-CoV-2, including a mutated form of nsp5, the catalytic dead mutant termed nsp5_c145a, affects the protein network regulating vascular functionality. Moreover, once the PPI model was validated with our experimental data, we applied it to more than 250 proteins that have been identified in the literature as affected by the SARS-CoV-2 proteins. This enabled us to pinpoint the more dominant SARS-CoV-2 proteins and chart their effects. Overall, this work shows how each of the SARS-CoV-2 proteins differentially affects vascular functionality; moreover, once the model was validated, we applied it to identify how SARS-CoV-2 proteins interact with proteins that have been significantly correlated with changes in cell functionality.

Results
SARS-CoV-2 proteins impair barrier properties affecting cell-junction proteins
Increasing numbers of studies indicate a significant role for the vasculature in the physiological response to SARS-CoV-2. However, neither the exact molecular mechanism that leads to these effects nor the individual contribution of any of the SARS-CoV-2 proteins is known. Plasmids encoding SARS-CoV-2 proteins were cloned into lentivirus vectors, with eGFP-encoding vector used as a negative control. To shed light on the vascular response to the virus, HUVECs were cultured on different platforms, transduced with these lentiviral particles, and assessed for the effects of the virus proteins on different functionalities. Culturing HUVEC on Transwells or glass coverslips (Figure 2a) allowed us to identify how the specific proteins affect endothelial functionality. To ensure proper infection, the control vector included a GFP label, which enabled us to estimate infection efficiency at around 70% (Figure 2a). Since the most basic function of the endothelium is to serve as a barrier, we sought to identify the changes in endothelium permeability in response to the SARS-CoV-2 proteins, and to pinpoint which of these proteins have the most significant effect. Barrier functions and properties were measured via trans-epithelial-endothelial electrical resistance (TEER), a standard method that identifies changes in impedance values, reflecting the integrity and permeability of the cell monolayer (Srinivasan et al., 2015). The GFP control and nine SARS-CoV-2 proteins did not show any significant change in TEER values (compared to the untreated condition), whereas 18 of the SARS-CoV-2 proteins caused significant changes in value (see plot in Figure 2b). The most dominant permeability changes were observed with nsp5_c145a, nsp13, nsp7, orf7a, and nsp2, with a 20–28% decrease in TEER values (Figure 2—figure supplement 1, and Figure 2c), in which the different SARS-CoV-2 proteins are listed and the gradual color change from red to violet represents the progressive reduction in TEER values. Figure 2—figure supplement 1 shows the comparison in TEER values before the infection and 3 and 4 days after the infection, showing that the permeability changes in the cells exposed to the viral proteins are maintained.

Next, we analyzed some of the proteins that exhibited the most significant (nsp2, nsp5_c145a, and nsp7) or least significant (S) changes in TEER value for changes in expression of the cell-junction
| SARS-CoV-2 | General impact |
|------------|----------------|
| **Structural proteins** | |
| S (spike) | Spike protein, mediates binding to ACE2, fusion with host membrane. Surface glycoprotein, needs to be processed by cellular protease TMPRSS2 (Gordon et al., 2020). |
| M (membrane) | Membrane glycoprotein, the predominant component of the envelope. A major driver for virus assembly and budding (Gordon et al., 2020). |
| E (envelope) | Envelope protein, involved in virus morphogenesis and assembly. Coexpression of M and E is sufficient for virus-like particle formation and release (Gordon et al., 2020). |
| N (nucleocapsid) | Nucleocapsid phosphoprotein binds to RNA genome (Gordon et al., 2020). |
| **Nonstructural proteins** | |
| nsp1 | Leader sequence, suppresses host antiviral response. Antagonizes interferon induction to suppress host antiviral response (Gordon et al., 2020). |
| nsp2 | Interferes with host cell signaling, including cell cycle, cell-death pathways, and cell differentiation. May serve as an adaptor for nsp3. Not essential for virus replication, but deletion of nsp2 diminishes viral growth and RNA synthesis (Gordon et al., 2020; Procko, 2020). |
| nsp3 | nsp3–nsp4–nsp6 complex involved in viral replication. Functions as papain-like protease (Gordon et al., 2020). |
| nsp4 | nsp3–nsp4–nsp6 complex involved in viral replication (Gordon et al., 2020). The complex is predicted to nucleate and anchor viral replication complexes on double-membrane vesicles in the cytoplasm (mitochondria). |
| nsp5 | Inhibits interferon I signaling processes by intervening in the NF-κB process and breaking down STAT one transcription factor. Functions as 3-chymotrypsin-like protease, cleaves the viral polyprotein (Gordon et al., 2020). |
| nsp5_c145a | Catalytic dead mutant of nsp5 (Gordon et al., 2020). |
| nsp6 | nsp3–nsp4–nsp6 complex involved in viral replication. Limits autophagosome expansion. Components of the mitochondrial complex V (the complex regenerates ATP from ADP) copurify with nsp6 (Gordon et al., 2020). |
| nsp7 | Cofactor of nsp12. nsp7–nsp8 complex in part of RNA polymerase (nsp7, 8, 12 – replication complex). Affects electron transport, GPCR signaling, and membrane trafficking (Gordon et al., 2020; Peng et al., 2020b; Romano et al., 2020; Hillen et al., 2020). |
| nsp8 | Cofactor of nsp12. nsp7–nsp8 complex in part of RNA polymerase. Affects the signal recognition particle and mitochondrial ribosome (Gordon et al., 2020; Peng et al., 2020b; Romano et al., 2020; Chi et al., 2003). |
| nsp9 | ssRNA binding protein (can bind both DNA and RNA, but prefers ssRNA). Interacts with the replication complex (nsp7, 8, 12) (Cornillez-Ty et al., 2009). |
| nsp10 | Cofactor of nsp16 and nsp14 (Romano et al., 2020). Essential for nsp16 methyltransferase activity (stimulator of nsp16). Zinc finger protein essential for replication (Gordon et al., 2020; Peng et al., 2020b). |
| nsp11 | Unknown function. |
| nsp12 | Functions as an RNA-direct RNA polymerase, the catalytic subunit. Affects the spliceosome (Gordon et al., 2020; Peng et al., 2020b; Romano et al., 2020; Hillen et al., 2020). |
| nsp13 | Has helicase and 5' triphosphatase activity. Initiates the first step in viral mRNA capping nsp13,14,16 installs the cap structure onto viral mRNA in the cytoplasm instead of in the nucleus, where the host mRNA is capped (Gordon et al., 2020; Peng et al., 2020b; Romano et al., 2020; Ivanov et al., 2004). |

Table 1 continued on next page
proteins such as CD31 (Figure 2d and e), cadherin 1–5, occludin, and ZO 1–3 (presented later), indicating altered barrier functions. Analysis of the immunocytochemistry (ICC) (Figure 2d and e) showed, as expected, that nsp2, nsp5_c145a, and nsp7 significantly reduce the expression levels of CD31 compared to the untreated, eGFP, and S conditions, suggesting a deterioration in barrier function. Hence, these data show a differential effect of SARS-CoV-2 proteins on endothelial functionality and provide a mechanistic explanation for the reduction in endothelial integrity.

**Increased endothelial inflammatory response caused by SARS-CoV-2 proteins**

It is known that SARS-CoV-2 can cause a severe cytokine storm (Pum et al., 2021; Wang et al., 2020a) and a significant increase in coagulation-related pathologies. As we were interested in identifying the role of the vasculature in these observations, we stained and analyzed the expression level of VWF (Figure 3a and b), which is highly correlated with coagulation (Rietveld et al., 2019). Similar to the CD31 staining, we characterized only those proteins that resulted in a significant decrease in TEER values (nsp2, nsp5_c145a, and nsp7). As shown in Figure 3a and b, the control samples did not exhibit marked expression of VWF, whereas the cells transfected with nsp2, nsp5_c145a, and nsp7 showed a significant change in VWF expression. Moreover, as VWF is also associated with increased inflammation (Kawecki et al., 2017), we monitored changes in cytokine expression due to the different SARS-CoV-2 proteins (Figure 3c). We were particularly interested in IL-6, which has been identified as one of the most dominant cytokines expressed due to SARS-CoV-2 infection (Wang et al., 2020a; Akbari and Rezaie, 2020; Peruzzi et al., 2020; Liao et al., 2020b; Liao et al., 2020a). We observed that 13 out of the 26 proteins caused an increase in IL-6 secretion, 3 of which had resulted in a decrease in barrier function and increased VWF expression.
Correlation between vascular permeability impairment and viral proteins

We then investigated how SARS-CoV-2 causes the observed changes in HUVECs permeability. We collected sets of proteins responsible for specific functionalities of endothelial cells. We also constructed an integrated viral–host and host–host PPI network. For each viral protein and each prior functional set, we measured the network proximity between the viral protein and the human functional set using a network propagation algorithm. We scored the significance of these propagation calculations by comparing them to those obtained on random PPI networks with the same node degrees. Proteins receiving high and significant scores were most likely to interact with the specific SARS-CoV-2 protein and thus might cause the observed functional changes. When comparing the overall effects of the 26 SARS-CoV-2 proteins on endothelial TJ proteins (e.g., cadherin 1–5, occludin, and ZO 1–3), we found a correlation between the effects of the SARS-CoV-2 proteins and TEER values (Figure 4a). Moreover, some of the proteins that significantly affected the TEER parameters (Figure 2c) were also observed to be significantly proximal to the permeability-related set. These included nsp2, nsp7, and nsp13 (Figure 4a). Our algorithm identified cadherin-2, α-catenin, β-catenin, δ-catenin, and ZO 1 and 2 as the most susceptible proteins to SARS-CoV-2 infection (Figure 4b).

To validate our PPI network model, we performed immunostaining of some TJ proteins (β-catenin, cadherin-5, ZO-1, and occludin) of HUVEC transfected with viral proteins and to compare it to the model prediction. Similar to the CD31 staining, we characterized only those proteins that significantly decreased TEER values (nsp2, nsp5_c145a, and nsp7) compared to the eGFP and untreated condition (Figure 5). As shown in Figure 5a–c, the cells transfected with nsp2, nsp5_c145a, and nsp7 showed a significant reduction in the β-catenin, cadherin-5, and ZO-1 intensity, confirming the ability of the SARS-CoV-2 proteins to impair endothelial permeability.

Figure 2. Effect of severe acute respiratory syndrome (SARS)-CoV-2 proteins on human umbilical vein endothelial cell (HUVEC) at day 3. (a) Bright-field and fluorescent image of infected eGFP HUVEC, scale bar: 50 µm; (b) changes in barrier functions as a result of SARS-CoV-2 proteins were assessed by trans-epithelial-endothelial electrical resistance (TEER) measurement. Note the statistical differences compared to the untreated control condition, assessed by F-statistic with two-way ANOVA test, followed by the Holm–Sidak test for multiple comparisons; (c) color map showing a gradual decrease in TEER values compared to the untreated condition at day 3; (d) immunocytochemistry (ICC) for CD31 (green) and Hoechst (blue) for the three specified conditions, scale bar: 20 µm; (e) analysis of CD31 expression levels.

The online version of this article includes the following figure supplement(s) for figure 2:

Figure supplement 1. Effect of severe acute respiratory syndrome (SARS)-CoV-2 proteins on human umbilical vein endothelial cell (HUVEC) functionality.
Once the model was validated, we used it to identify how the individual SARS-Cov-2 proteins affect nine other different vascular endothelial cells. As a starting point, we created a table (Table 2) (based on the literature) where we compared the expression of 12 different TJ proteins across nine different types of endothelial cells. We then applied the network-based model to identify which endothelial cells are more susceptible to the different SARS-Cov-2 proteins. As can be seen in Figure 6, there are significant differences in the response of various viral proteins on different types of vascular endothelial cells. For example, the viral proteins nsp13, nsp11, orf6, and S seem to have a significant effect on the different types of vascular endothelial cells, according to the network score detected. However, the proteins m, E, n, nsp12, and nsp8 are the less interactive with the vascular cells.

As our network propagation model is highly correlated with our experimental results, we applied it to other physiological systems that are known to be affected by SARS-Cov-2. We created a list of all proteins that are known to be affected by the SARS-Cov-2 proteins according to the literature (Supplementary file 1A, white columns). The table was composed of both proteins identified experimentally via western blot, proteomics, and immunohistochemistry (marked in blue) and those identified clinically as being highly correlated with loss of specific functionality in specific tissues (marked

---

Figure 3. Human umbilical vein endothelial cell (HUVEC) response to specific proteins. (a) Confocal reconstructions of HUVEC stained for von Willebrand factor (VWF) (green) and Hoechst (blue) for three conditions: control (untreated), eGFP, and nsp5_c145a, scale bar: 20 µm; (b) analysis of VWF expression levels; (c) fold change of interleukin (IL)-6 in response to the different proteins.
Figure 4. Correlation between viral protein effect on permeability and proximity to permeability-related proteins in a protein–protein interaction (PPI) network. (a) Correlation of adjusted p-value versus permeability (Pearson = 0.295); (b) proximity between vascular proteins and the viral proteins.
We then applied the network-based model to identify which proteins in Supplementary file 1A are most susceptible to the different SARS-CoV-2 proteins. As can be seen in Figure 7—figure supplements 2–7, Supplementary file 1A and B, specific SARS-CoV-2 proteins were identified as affecting specific proteins in specific tissues. As expected, most of the SARS-CoV-2 proteins affected more than one protein, the most salient being nsp11, nsp4, and nsp7 (Figure 7b), each of which was predicted to affect more than 40 different proteins. An additional parameter that should be considered is the protein's ‘distance’ from the viral proteins. This value represents the number of hops in the PPI network from a given protein to the viral proteins, where a value of 1 represents a direct viral–host connection. We hypothesized that the closer the distance between the viral proteins and the given protein, the more significant the viral effect. Supplementary file 1A (gray columns) and Figure 7c present the calculated distances. Most of the identified proteins in Supplementary file 1A were classified with a distance of 1 or 2 from the virus, suggesting more severe putative effects. A very clear example, are the T cells, macrophages, lung epithelial and cardiomyocytes which show that the most significant effect was by the viral proteins which present a close connection with the relative cell proteins reported. This suggest a potential effect on the related functional or metabolic pathway (Supplementary file 1A).

Figure 5. Tight-junctions impairment by severe acute respiratory syndrome (SARS)-CoV-2 proteins. Immunocytochemistry (ICC) for (a) β-catenin (green), (b) cadherin-5 (green), (c) ZO-1 (green), (d) occludin (green), and Hoechst (blue) for five specified conditions: untreated, eGFP, nsp2, nsp5-c1451, and nsp7. Relative quantification is shown for each tight junction (TJ) protein for all five conditions on the right. Scale bar: 50 µm.
Due to the impact of SARS-CoV-2, many studies have looked at the physiological responses to the virus (Lee et al., 2021; Libby and Lüscher, 2020; Siddiqi et al., 2020; Teuwen et al., 2020; Chioh et al., 2020). In this work, we sought to identify how specific SARS-CoV-2 proteins affect the vasculature by assessing the effect of individual SARS-CoV-2 proteins on endothelial cells (HUVEC).

Table 2. Comparison of tight junction (TJ) proteins expression among different types of vascular endothelial cells.

| Endothelial cells type                     | TJ proteins |
|-------------------------------------------|-------------|
|                                           | Cadherin-2 | Cadherin-3 | Cadherin-4 | Cadherin-5 | β-1-Catenin | β-Catenin | α-Catenin | Occludin | Claudin-5 | ZO-1 | ZO-2 | ZO-3 |
| Human pulmonary artery endothelial cells (HPAECs) (Nakato et al., 2019; Chi et al., 2003; Ivanov et al., 2004; Ferseri et al., 2008; DiStefano et al., 2014; Zeba et al., 2013; Yuan et al., 2012; Wang et al., 2011) | + | − | − | + | + | + | + | + | + | + | + | + | − |
| Human umbilical vein endothelial cells (HUVECs) (Nakato et al., 2019; Chi et al., 2003; Ferreri et al., 2008; Wu et al., 2008; Dean et al., 2009; Polus et al., 2006; DeBuske et al., 2010; Wessells et al., 2009) | + | + | + | + | + | + | + | + | + | + | + | + | + |
| Human umbilical artery endothelial cells (HUAECs) (Nakato et al., 2019; Chi et al., 2003; Davis et al., 2003; Ikuno et al., 2017; Kevil et al., 1998; Kluger et al., 2013) | − | + | − | + | + | + | − | + | + | + | + | + | + |
| Human great saphenous vein endothelial cells (HGSVECs) (Nakato et al., 2019; Chi et al., 2003; Latif et al., 2006; Murakami et al., 2008) | − | − | − | − | + | + | − | + | + | + | + | + | + |
| Human common carotid artery endothelial cells (HCCaECs) (Nakato et al., 2019; Chi et al., 2003) | − | − | − | + | + | − | + | + | + | + | + | + | + |
| Human aortic endothelial cells (HAAECs) (Nakato et al., 2019; Chi et al., 2003; Wessells et al., 2009; Wu et al., 2004, Pinto et al., 2018) | − | − | − | + | + | − | + | + | + | + | + | + | + |
| Human coronary artery endothelial cells (HCAECs) (Nakato et al., 2019; Chi et al., 2003; Wessells et al., 2009; Wu et al., 2009, Pinto et al., 2018) | − | − | − | + | + | − | + | + | + | + | + | + | + |
| Human endocardial cells (HENDCs) (Nakato et al., 2019; Chi et al., 2003; Vestweber et al., 2009; Bao et al., 2017) | + | − | − | + | − | + | + | + | + | + | + | + | − |
| Human renal artery endothelial cells (HRAECs) (Nakato et al., 2019; Chi et al., 2003; Maciel et al., 2018) | − | − | + | + | − | + | + | + | + | + | + | + | − |

Discussion

Due to the impact of SARS-CoV-2, many studies have looked at the physiological responses to the virus (Lee et al., 2021; Libby and Lüscher, 2020; Siddiqi et al., 2020; Teuwen et al., 2020; Chioh et al., 2020). In this work, we sought to identify how specific SARS-CoV-2 proteins affect the vasculature by assessing the effect of individual SARS-CoV-2 proteins on endothelial cells (HUVEC).
approach has significant advantages: it enables pinpointing and isolating how each of the SARS-CoV-2 proteins independently affects the endothelial response, and directly measuring endothelial functionality. The HUVEC model, derived from the umbilical cord, is physiologically representative of the human vascular endothelium, allowing the study of the physiological and pathological conditions as well as the effects of novel drugs on human endothelium (Bouïs et al., 2001; Medina-Leyte et al., 2020). Among technical advantages, cultured HUVECs are a simple in vitro vascular endothelial model, particularly suitable for studying endothelial properties and dynamics as well as the putative role of adhesion molecules, the synthesis of extracellular proteins and blood vessel maturation (Vailhé et al., 2001).

The current study showed that almost 70% (18 out of 26) of the SARS-CoV-2 proteins affect endothelial barrier integrity; however, the most significant proteins were nsp2, nsp5_c145a, and nsp7, which also induced upregulated expression of the coagulation factor VWF and cytokine release. These critical facts can shed light on the multiple pathologies observed in SARS-CoV-2 infection, including cytokine storm, increased coagulation and related diseases (e.g., heart attack and stroke) (Lee et al., 2021; Aid et al., 2020), increased cardiovascular disease, and increased neurological symptoms. The results presented here showed an effect of in vitro cultured endothelial cells, which may lead to vasculature leakiness, consequently causing exotoxicity (i.e., the penetration of toxic reagents from the blood into the brain). While there are many parameters associated with functional changes, the use of advanced tools, including network-based analysis, enabled us to elucidate the specific proteins and the specific interactions that are predicted to cause these changes. The PPI network enabled us to predict that the changes observed in barrier function are possibly due to interactions between host proteins such as cadherin 2, α-catenin, β-catenin, δ-catenin, and ZO 1 and 2, and at least with the viral proteins nsp2, nsp5_c145a, and nsp7. Moreover, we validated our PPI model performing further immunostaining analysis demonstrating not only the ability of the viral proteins to strongly impair TJ
Figure 7. Protein identification using protein–protein interaction (PPI). (a) PPI results for the severe acute respiratory syndrome (SARS)-CoV-2 proteins that have a significant effect on the proteins presented in SI Table 1 for each system; (b) number of proteins affected by each SARS-CoV-2 protein, as calculated by PPI; (c) number of proteins with a specific distance factor from the viral proteins (also shown in SI Table 1).

The online version of this article includes the following figure supplement(s) for figure 7:

Figure supplement 1. Cardiomyocytes.

Figure supplement 2. Enterocytes.

Figure supplement 3. Lymphocytes.

Figure 7 continued on next page
expression, but also to confirm the data predicted by our model in which some TJ proteins can be more affected than others.

PPI analysis revealed a highly correlated effect of nsp7 and nsp13 on β-catenin in endothelial cells (Figure 4b; Jung et al., 2020a; Lengfeld et al., 2017). Interestingly, neither nsp2 nor nsp5_c145a affected a high number of proteins (Figure 7b), whereas nsp7 did, as identified by the network. Analyzing the repertoire of SARS-CoV-2 proteins, we see almost no effect of the structural proteins; rather, mostly nonstructural and open reading frame proteins affected HUVEC functionality, manifested as decreased barrier function and increased cytokine secretion (Figures 2 and 3). While the nonstructural proteins are mainly responsible for replicating viral RNA, the open reading frame proteins are related to counteraction with the host immune system; some of these are localized to the mitochondria and have been shown to alter the mitochondrial antiviral signaling pathway (Miller et al., 2021). We found that the proteins most affecting barrier function (decreased TEER and decreased CD31, β-catenin, cadherin-5, and ZO-1 expression) and cytokine response (IL-6 secretion and VWF expression) were nsp2, nsp5_c145a, and nsp7 (Figure 2; Figure 3; Figure 6); nsp7 forms a replication complex with nsp8 and nsp12 that is essential for viral replication and transcription (Cowen et al., 2017; Peng et al., 2020a). Peng et al., 2020b suggested that in the core polymerase complex nsp7–nsp8–nsp12, nsp12 is the catalytic subunit, and nsp7 and nsp8 function as cofactors. They further suggested that the mechanism of activation mainly involves the cofactors rather than the catalytic subunit (Peng et al., 2020b). This might explain why we saw mainly an effect of the cofactor proteins on endothelial cells and almost no effect of the catalytic subunit. Network interactions Diaz, 2020 have shown that nsp7 has the most interactions with the host, suggesting a potential target for the treatment of COVID-19. Moreover, no mutations were found in nsp7 compared to nsp2 or nsp5_c145a (Kausalhal et al., 2020), suggesting a conserved protein with a vital function in virus survival. The nsp13 protein has both helicase activity and 5’ triphosphatase activity, which play an important role in mRNA capping. We saw a significant effect of nsp13 on barrier function, but hardly any effect on cytokine secretion. Chen et al., 2020 suggested functional complexation between nsp8 and nsp12, the RdRp (RNA-dependent RNA polymerase) replication complex, and nsp13. Given the fact that we observed a substantial effect of nsp7 – one of the proteins of the replication complex – and an effect of nsp13 on HUVEC barrier function, complexation of nsp13 with the replication complex might indicate an important role for this complex in the impaired functionality of the HUVECs, and therefore in the propagation of the disease, and the known vascular damage seen in COVID-19 patients. As suggested by our model, nsp13 seems to have a strong effect also on other types of vascular endothelial cells (Figure 6) as well as on all cell types (Figure 7a), positioning nsp13 as one of the main targets for disease treatment.

It is important to note that the comparison between the different endothelial cell types revealed exciting differences in the TJ protein expression, which correlate to the different properties of the different cell types (Nakato et al., 2019). One of the major differences was that some endothelial cell lines do not have cadherin at all (e.g., HAoEC), or very limited amount of cadherin (e.g., HPAEC, HUAEC, HGSVEC). Our model suggests that some endothelial types (e.g., HUVEC, HUAEC, HGSVEC, HCAEC) are more susceptible to the SARS-CoV-2 virus. It, therefore, suggests that the treatment of one type of endothelial cell might be different from another type but offers the PPI model as a tool for initial prediction. Overall, the combination of identifying the differences in the TJ protein expression between the different endothelial cells and the use of the PPI model enabled us to pinpoint the differences in susceptibility to the disease and to identify which specific proteins have the most significant effect.

Many studies have looked at the SARS-CoV-2 interaction with nonpulmonary/nonvascular tissues (e.g., neurons, hepatocytes, immune components such as lymphocytes, macrophages, etc.) (Lee et al., 2021), as pathological studies identified a viral effect on these tissues, despite their very limited amount, or lack of ACE2 receptors. To better understand how SARS-CoV-2 interacts with and affects...
other tissues, we consolidated all of the proteins currently known to be affected by the virus into Supplementary file 1A. It is interesting to note that the most dominant SARS-CoV-2 proteins are nsp4, nsp11, and nsp7. Davies et al., 2020, identified the interaction of nsp2 with nsp4, both involved in endoplasmic reticulum (ER) calcium signaling and mitochondrial biogenesis. This suggests a new functional role in the host ER and mitochondrial organelle contact process and calcium homeostasis.

By now it is clear that vasculature plays a significant role in the physiological response to the virus. However, it is still unclear how the virus affects the vasculature, and if it can be found in the blood. This is a critical question, as it has significant consequences on the extent of the virus's ability to affect the vasculature. Current studies demonstrate that the pulmonary vasculature is significantly affected and is one of the dominant triggers for the pathologies mentioned above. However, involvement with the rest of the vasculature is still unclear, as is whether the virus can be found in an active form in the blood circulation (Peng et al., 2020a; Chang et al., 2020; Orologas-Stavrou et al., 2020; Andersson et al., 2020; Escribano et al., 2020; Wang et al., 2020b). Some studies suggest that even if there are traces of SARS-CoV-2 in the blood, it is not in an active form and cannot cause disease or a systemic response (Andersson et al., 2020). On the other hand, some studies suggest that SARS-CoV-2 can be found in the blood, and can induce the disease and cause both cellular and systemic dysfunction (Peng et al., 2020a; Chang et al., 2020; Escribano et al., 2020). While this question is beyond the scope of this work, it is important to note that if future studies do identify the active form of SARS-CoV-2 in human blood, then the implications of our findings will apply to this systemic response as well (Ahmed et al., 2020; Park et al., 2020).

As already noted, the pathology is probably a combination of multiple conditions and pathways activated by the different proteins. However, our findings might open new avenues for future therapeutics. Moreover, most of the proteins that were identified as affected by SARS-CoV-2 had a distance factor of at most three to the human and viral proteins. This coincides with the current dogma, whereby proteins that have a shorter distance between them are more likely to be affected.

While beneficial, our approach has two major limitations: (a) our inability to identify the effect of multiple proteins and (b) our neglect of the effect of the coronavirus structure and binding on the cellular response. The former point can be overcome by expressing combinations of different SARS-CoV-2 proteins. However, since the SARS-CoV-2 expresses 29 proteins, there are about $9 \times 10^{30}$ possible protein combinations. Therefore, we decided to focus on individual proteins and allow further studies to pursue any combinations of interest. Regarding the latter limitation, we did not include the coronavirus structure (including the ACE2 receptors) in this study, because many studies have already demonstrated the cellular response to this structure (Chioh et al., 2020; Yang et al., 2020; Procko, 2020), and how tissues that do not have significant ACE2 expression (neurons, immune components such as B and T lymphocytes, and macrophages) are affected by the virus remains an open question.

Conclusions
Accumulating clinical evidence suggests that COVID-19 is a disease with vascular aspects. However, only a few studies have identified the specific role of each of the SARS-CoV-2 proteins in the cellular response leading to vascular dysfunctions. In this work, we characterized the endothelial response to each of 26 SARS-CoV-2 proteins and identified those that have the most significant effect on the barrier function. In addition, we used PPI network-based analysis to predict which of the endothelial proteins is most affected by the virus and to identify the specific role of each of the SARS-CoV-2 proteins in the observed changes in systemic protein expression. Overall, this work identified which of the SARS-CoV-2 proteins are most dominant in their effect on the physiological response to the virus. We believe that the data presented in this work will give us better insight into the mechanism by which the vasculature and the system respond to the virus, and will enable us to expedite drug development for the virus by targeting the identified dominant proteins.

Materials and methods
Generation of lentiviral SARS-CoV-2 plasmids
Plasmids encoding the SARS-CoV-2 open reading frames proteins and eGFP control were a kind gift of Nevan Krogan (Addgene plasmid #141367–141395). Plasmids were acquired as bacterial LB–agar stabs and used per the provider's instructions. Briefly, each stab was first seeded in LB agar (Bacto
Agar; BD Biosciences, San Jose, CA) in 10 cm plates. Then, single colonies were inoculated into flasks containing LB (BD Difco LB Broth, Lennox) and 100 µg/ml penicillin (Biological Industries, Beit HaEmek, Israel). Transfection-grade plasmid DNA was isolated from each flask using the ZymoPURE II Plasmid Maxiprep Kit (Zymo Research, Irvine, CA) according to the manufacturer’s instructions.

**Lentivirus preparation**

HEK293T cells (ATCC, Manassas, VA) were seeded in 10 cm cell culture plates at a density of 4 × 10^6 cells/plate. The cells were maintained in 293T medium composed of DMEM high glucose (4.5 g/l; Merck, Rahway, NJ) supplemented with 10 % fetal bovine serum (FBS; Biological Industries), 1 × NEAA (Biological Industries), and 2 mM L-alanine–L-glutamine (Biological Industries, Israel). Lentiviral stocks, pseudo-typed with VSV-G, were produced in HEK293T cells as previously described (Kutner et al., 2009). Briefly, each of the plLVX plasmids containing the SARS-CoV-2 genes or EGFP for control were cotransfected with third-generation lentivirus helper plasmids at equimolar ratio; 48 hr later, the lentivirus-containing medium was collected and supernatant was clarified by centrifugation (500 g, 5 min) and filtration (0.45 µm, Millex-HV, Merck Millipore, Burlington, MA). All virus stocks were aliquoted and stored at –80 °C until thawed for subsequent use.

**Endothelial cell culture**

HUVECs (C-12200, PromoCell GmbH, Heidelberg, Germany, tested negative for mycoplasma contamination) were used to test each viral protein’s impact on vascular properties. After thawing, the HUVECs were expanded in low-serum endothelial cell growth medium (PromoCell) at 37 °C with 5 % CO2 in a humidifying incubator, and used at passage p4–p6. Cells were grown to 80–90% confluence before being transferred to transparent polyethylene terephthalate Transwell supports (0.4 µm pore size, Greiner Bio-One, Austria) or a glass-bottom well plate (Cellvis, Mountain View, CA). Before seeding, the uncoated substrates were treated with Entactin-Collagen IV-Laminin (ECL) Cell Attachment Matrix (Merck) diluted in DMEM (10 µg/cm²) for 1 hr in the incubator. Then, the HUVECs were harvested using a DetachKit (PromoCell), were seeded inside the culture platforms at a density of 250,000 cells/cm², and grown for 3 days. Then viral infection with the different plasmids was performed and its impact on cell behavior was tested 3 days later.

**TEER measurement**

The barrier properties of the endothelial monolayer were evaluated by TEER measurements, 3 and 4 days after viral infection. TEER was measured with the Millicell ERS-2 Voltohmmeter (Merck Millipore). TEER values (Ω cm²) were calculated and compared to those obtained in a Transwell insert without cells, considered as a blank, in three different individual experiments, with two inserts used for each viral protein.

**Immunofluorescence**

HUVEC plated on glass-bottom plates were rinsed in phosphate buffered saline (PBS) and fixed in 4 % paraformaldehyde (Sigma-Aldrich, Rehovot, Israel) for 20 min at RT, 5 days after viral infection. ICC was carried out after permeabilization with 0.1 % Triton X-100 (Sigma-Aldrich, Rehovot, Israel) in PBS for 10 min at RT and blocking for 30 min with 5 % FBS in PBS. The following primary antibodies were applied overnight in PBS at 4 °C: rabbit anti-VWF (Abcam, Cambridge, UK), rabbit anti-CD31 (Abcam) against platelet endothelial cell adhesion molecule 1 (PECAM1), rabbit anti-β-catenin (Cell Signaling Technology, Danvers, MA), rabbit anti-cadherin-5 (Cell Signaling Technology, Danvers, MA), rabbit anti ZO-1 (Cell Signaling Technology, Danvers, MA), rabbit anti-occludin (Cell Signaling Technology, Danvers, MA). Cells were then washed three times in PBS and stained with the secondary antibody, anti-rabbit Alexa Fluor 488 (Invitrogen, Carlsbad, CA), for 1 hr at RT. After four washes with PBS, cells were incubated with Hoechst in PBS for 10 min at RT to stain the nuclei. After two washes with PBS, imaging was carried out using an inverted confocal microscope (Olympus FY3000-IX33) with suitable filter cubes and equipped with 20× (0.8 NA), 40× (0.95 NA), and 60× (1.42 NA) objectives. Image reconstruction and analysis were done using open-source ImageJ software (Schindelin et al., 2012).
Network analysis
We scored the effect of each viral protein on selected human proteins using network propagation (Cowen et al., 2017). Specifically, a viral protein was represented by the set of its human interactors (Hu et al., 2021); each of these received a prior score, equal to 1/n, where n is the size of the interactor set; these scores were propagated in a network of PPI (Almozlino et al., 2017). To assess the statistical significance of the obtained scores, we compared them to those computed on 1000 randomized networks that preserve node degrees. The PPI score was then compared versus the other random networks (this is empirical p-value). p-Values were adjusted for multiple testing using Benjamini–Hochberg FDR approach. For display purposes, the plotted p-value is the negative log of the p-value, which means numbers are non-negative and the higher is the more significant.

Quantitative ELISA for IL-6
ELISA was performed on conditioned medium of infected HUVEC 3 days postinfection, according to the manufacturer’s recommendations (PeproTech Rehovot, Israel).

Statistical analysis
The results are presented as mean ± SD, unless otherwise indicated. Statistically significant differences among multiple groups were evaluated by F-statistic with two-way ANOVA, followed by the Holm–Sidak test for multiple comparisons (GraphPad Prism 8.4.3). The difference between the two data sets was assessed and p < 0.05 was considered statistically significant.

Acknowledgements
BMM was supported by the Azrieli Foundation, Israel Science Foundation (ISF grant: 2248/19), ERC SweetBrain 851765, TEVA, The Aufzien Family Center for the Prevention and Treatment of Parkinson’s Disease at Tel Aviv University, Zimin, Israel Ministry of Science and Technology (Grant No. 3–17351), and TCCP. UA was supported by the Israel Science Foundation (ISF grant 953/16), TEVA, The Aufzien Family Center for the Prevention and Treatment of Parkinson’s Disease at Tel Aviv University, the German Research Foundation (DFG) (NA: 207/10–1) and the Taube/Koret Global Collaboration in Neurodegenerative Diseases. RS was supported by the Israel Science Foundation (ISF grant 2417/20), within the Israel Precision Medicine Partership program. The work of YN, AE, andKI was supported by European Research Council Consolidator Grant OCLD (project no. 681870).

Additional information

| Funding            | Grant reference number | Author                          |
|--------------------|-------------------------|---------------------------------|
| Israel Science Foundation | 2248/19               | Rossana Rauti                   |
|                     |                        | Yael Leichtmann-Bardoogo        |
|                     |                        | Rina Tamir                      |
|                     |                        | Victoria Miller                 |
|                     |                        | Tal Babich                      |
|                     |                        | Kfir Shaked                     |
|                     |                        | Ben Meir Maoz                   |
| Azrieli Foundation  | SweetBrain 851765      | Rossana Rauti                   |
|                     |                        | Yael Leichtmann-Bardoogo        |
|                     |                        | Ben Meir Maoz                   |
| Horizon 2020        | SweetBrain 851765      | Rossana Rauti                   |
|                     |                        | Yael Leichtmann-Bardoogo        |
|                     |                        | Ben Meir Maoz                   |
Funder | Grant reference number | Author
--- | --- | ---
Aufzien Family Center for the Prevention and Treatment of Parkinson’s Disease |  | Rossana Rauti, Meishar Shahoha, Yael Leichtmann-Bardoogo, Eyal Paz, Rina Tamir, Victoria Miller, Tal Babich, Kfir Shaked, Uri Ashery, Ben Meir Maoz
Deutsche Forschungsgemeinschaft | 207/10-1 | Rami Nasser, Avner Ehrlich, Konstantinos Ioannidis, Yaakov Nahmias, Roded Sharan
Teva Pharmaceutical Industries |  | Yael Leichtmann-Bardoogo, Ben Meir Maoz
Zimin |  | Yael Leichtmann-Bardoogo, Ben Meir Maoz
Ministry of Science and Technology, Israel | 3-17351 | Rossana Rauti, Yael Leichtmann-Bardoogo, Ben Meir Maoz
TCCP |  | Uri Ashery, Ben Meir Maoz
Israel Science Foundation | 953/16 | Rina Tamir, Victoria Miller, Tal Babich, Kfir Shaked, Ben Meir Maoz

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions
Rossana Rauti, Conceptualization, Formal analysis, Methodology, Project administration, Writing – original draft; Meishar Shahoha, Conceptualization, Data curation, Investigation, Methodology, Visualization; Yael Leichtmann-Bardoogo, Conceptualization, Data curation, Investigation, Methodology, Visualization, Writing – original draft; Rami Nasser, Roded Sharan, Formal analysis, Software; Eyal Paz, Methodology, Writing - review and editing; Rina Tamir, Victoria Miller, Tal Babich, Kfir Shaked, Formal analysis, Investigation; Avner Ehrlich, Konstantinos Ioannidis, Yaakov Nahmias, Methodology, Resources; Uri Ashery, Funding acquisition, Investigation, Supervision, Writing – original draft; Ben Meir Maoz, Conceptualization, Funding acquisition, Project administration, Supervision, Visualization, Writing – original draft

Author ORCIDs
Rossana Rauti [http://orcid.org/0000-0001-8569-0810](http://orcid.org/0000-0001-8569-0810)
Meishar Shahoha [http://orcid.org/0000-0001-5947-484X](http://orcid.org/0000-0001-5947-484X)
Uri Ashery [http://orcid.org/0000-0001-6338-7888](http://orcid.org/0000-0001-6338-7888)
Ben Meir Maoz [http://orcid.org/0000-0002-3823-7682](http://orcid.org/0000-0002-3823-7682)

Decision letter and Author response
Decision letter [https://doi.org/10.7554/eLife.69314.sa1](https://doi.org/10.7554/eLife.69314.sa1)
Author response [https://doi.org/10.7554/eLife.69314.sa2](https://doi.org/10.7554/eLife.69314.sa2)

Additional files
Supplementary files
- Supplementary file 1. Protein change by SARS-Cov-2. (A) Documented change by severe acute respiratory syndrome (SARS)-Cov-2. (B) Significant target for each viral protein.
• Transparent reporting form
• Source data 1. The source data file contains all the data that was used for Figure 2, Figure 3, Figure 5, and Figure 2—figure supplement 1b.

Data availability
All data generated or analysed during this study are included in the manuscript and supporting files. The custom scripts available in GitHub: https://github.com/raminass/covid_networks, (copy archived at https://archive.softwareheritage.org/swh:1:rev:b239ae7e0e72b722beb6d694436068541ea28dbb).

References
Ahmed H, Sayed A, Munir M, Elberry MH, Sayed IM, Kamal MA, Negida A, Ebada MA, Bahbah El. 2020. A Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management. Current Pharmaceutical Design: 1–9. DOI: https://doi.org/10.2174/13816128126666202122162509, PMID: 3335050

Aid M, Busman-Sahay K, Vidal SJ, Maliga Z, Bondoc S, Starke C, Terry M, Jacobson CA, Wrijl L, Ducat S, Brook OR, Miller AD, Porto M, Pellegrini KL, Pino M, Hoang TN, Chadrashkear A, Patel S, Stephenson K, Bosinger SE, et al. 2020. Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. Cell 183: 1354–1366. DOI: https://doi.org/10.1016/j.cell.2020.10.005, PMID: 33065030

Akbari A, Rezaie J. 2020. Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia. Stem Cell Research & Therapy 11: 356. DOI: https://doi.org/10.1186/s13287-020-01866-6, PMID: 32795359

Almazino Y, Atias N, Silverbush D, Sharan R. 2017. ANAT 2.0: reconstructing functional protein subnetworks. BMC Bioinformatics 18: 495. DOI: https://doi.org/10.1186/s12859-017-1932-1, PMID: 29145805

Andersson MI, Arancibia-Carcamo CV, Auckland K, Baillie JK, Beneke T, Bibi S, Brooks T, Carroll M, Chait BT, Kapoor TM, Darst SA, Campbell EA. 2020. Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 RNA Replication-Transcription Complex. Cell 183: 356. DOI: https://doi.org/10.1016/j.cell.2020.10.011, PMID: 32835367

Bao X, Bhute VJ, Han T, Qian T, Lian X, Palecek SP. 2017. Human pluripotent stem cell-derived epicardial progenitors can differentiate to endocardial-like endothelial cells. Bioengineering & Translational Medicine 2: 191–201. DOI: https://doi.org/10.1002/btm2.10062, PMID: 29170757

Barbosa LC, Gonçalves TL, de Araujo LP, de Rosario L, Ferrer VP. 2021. Endothelial cells and SARS-CoV-2: An intimate relationship. Vascular Pharmacology 137: 106829. DOI: https://doi.org/10.1016/j.vph.2021.106829, PMID: 33422689

Bouis D, Hospers GA, Meijer C, Molena G, Mulder NH. 2001. Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research. Angiogenesis 4: 91–102. DOI: https://doi.org/10.1023/a:1012259529167, PMID: 11806248

Buzhdygan TP, DeOre BJ, Baldwin-Leclair A, Bullock TA, McGary HM, Khan JA, Razmpour R, Hale JF, Galie PA, Potula R, Andrews AM, Ramirez SH. 2020. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiology of Disease 146: 105131. DOI: https://doi.org/10.1016/j.nbd.2020.105131, PMID: 33054340

Chang L, Yan Y, Wang L. 2020. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfusion Medicine 1: 75–80. DOI: https://doi.org/10.1002/tmvr.2020.02.003, PMID: 32107119

Chen J, Malone B, Llewellyn E, Grasso M, Shelton PMM, Olinares PDB, Maruthi K, Eng ET, Vatandaslar H, Chait BT, Kapoor TM, Darst SA, Campbell EA. 2020. Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex. Cell 182: 1560–1573. DOI: https://doi.org/10.1016/j.cell.2020.07.033, PMID: 32783916

Chi JT, Chang HY, Haraldsen G, Jahnsen FL, Troyanskaya OG, Chang DS, Wang Z, Rockson SG, van de Rijn M, Botstein D, Brown PO. 2003. Endothelial cell diversity revealed by global expression profiling. PNAS 100: 10623–10628. DOI: https://doi.org/10.1073/pnas.1434429100, PMID: 12963823

Chiou PWJ, Fong SW, Young BE. 2020. Convalescent COVID-19 Patients Are Susceptible to Endothelial Dysfunction Due to Persistent Immune Activation. [medRxiv]. DOI: https://doi.org/10.1101/2020.11.16.20232835v1

Cornillez-Ty CT, Liao L, Yates JR, Kuhn P, Buchmeier MJ. 2009. Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling. Journal of Virology 83: 10314–10318. DOI: https://doi.org/10.1128/JVI.00842-09, PMID: 19640993

Cowen L, Ideker T, Raphael BJ, Sharan R. 2017. Network propagation: a universal amplifier of genetic associations. Nature Reviews. Genetics 18: 551–562. DOI: https://doi.org/10.1038/nrg.2017.38, PMID: 28607512

Davies JP, Almasy KM, McDonald EF, Plate L. 2020. Comparative Multiplexed Interactomics of SARS-CoV-2 and Homologous Coronavirus Nonstructural Proteins Identifies Unique and Shared Host-Cell Dependencies. ACS Infectious Diseases 6: 3174–3189. DOI: https://doi.org/10.1021/acsinfecdis.0c00500, PMID: 33263384

Davis MA, Ireton RC, Reynolds AB. 2003. A core function for p120-catenin in cadherin turnover. The Journal of Cell Biology 163: 525–534. DOI: https://doi.org/10.1083/jcb.200307111, PMID: 14610055
Microbiology and Infectious Disease

Dean WL, Lee MJ, Cummins TD, Schultz DJ, Powell DW. 2009. Proteomic and functional characterisation of platelet microparticle size classes. *Thrombosis and Haemostasis* 102: 711–718. DOI: https://doi.org/10.1160/TH09-04-243, PMID: 19806257

DeBusk LM, Boelte K, Min Y, Lin PC. 2010. Heterozygous deficiency of delta-catenin impairs pathological angiogenesis. *The Journal of Experimental Medicine* 207: 77–84. DOI: https://doi.org/10.1084/jem.20091097, PMID: 20048286

DeMaie L, Rouhanizadeh M, Reddy S, Sevanian A, Hwang J, Hsiai TK. 2006. Oxidized phospholipids mediate occludin expression and phosphorylation in vascular endothelial cells. *American Journal of Physiology. Heart and Circulatory Physiology* 290: H674-H683. DOI: https://doi.org/10.1152/ajpheart.00554.2005, PMID: 16172163

Díaz J. 2020. SARS-CoV-2 Molecular Network Structure. *Frontiers in Physiology* 11: 870. DOI: https://doi.org/10.3389/fphys.2020.00870, PMID: 32754056

DiStefano PV, Kuebel JM, Sarelius IH, Glading AJ. 2014. KRT1 protein depletion modifies endothelial cell behavior via increased vascular endothelial growth factor (VEGF) signaling. *The Journal of Biological Chemistry* 289: 33054–33065. DOI: https://doi.org/10.1074/jbc.M114.582304, PMID: 25320085

Escribano P, Álvarez-Uría A, Alonso R, Catalán P, Alcalá L, Muñoz P, Guinea J. 2020. Detection of SARS-CoV-2 antibodies is insufficient for the diagnosis of active or cured COVID-19. *Scientific Reports* 10: 19893. DOI: https://doi.org/10.1038/s41598-020-76914-5, PMID: 33199713

Ferrari DM, Minnear FL, Yin T, Kowalczyk AP, Vincent PA. 2008. N-cadherin levels in endothelial cells are regulated by monolayer maturity and p120 availability. *Cell Communication & Adhesion* 13: 33–39. DOI: https://doi.org/10.1080/10755560802440377, PMID: 18979298

Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O’Meara MJ, RezeljVV, Guo JZ, Swaney DL, Tummino TA, Hüttchenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Fousnard H, Batra J, Haas K, Modak M, Kim M, et al. 2020. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. *Nature* 583: 459–468. DOI: https://doi.org/10.1038/s41586-020-2286-9, PMID: 32353859

Hillen HS, Kokic G, Farmung L, Diemmann C, Tegunov D, Cramer P. 2020. Structure of replicating SARS-CoV-2 polymerase. *Nature* 584: 154–156. DOI: https://doi.org/10.1038/s41586-020-2368-8, PMID: 32438371

Hu B, Guo H, Zhou P, Shi ZL. 2021. Characteristics of SARS-CoV-2 and COVID-19. *Nature Reviews. Microbiology* 19: 141–154. DOI: https://doi.org/10.1038/s41579-020-00459-7, PMID: 33024307

Ikuno T, Masumoto H, Yamamizu K, Yoshioka M, Minakata K, Ikeda T, Sakata R, Yamashita JK, Rajasingh J. 2017. von Willebrand factor and inflammation. *Microcirculation* 24: 1285–1294. DOI: https://doi.org/10.1111/jth.13696, PMID: 28671350

Ivanov KA, Thiel V, Dobbe JC, van der Meer Y, Snijder EJ, Ziebuhr J. 2020a. Comparative Analysis of Primer-Probe Sets for SARS-CoV-2 Genome during the Beginning Months of the Outbreak in USA. *PLOS ONE* 15: E0173271. DOI: https://doi.org/10.1371/journal.pone.0173271, PMID: 28288160

Jung Y, Park GS, Moon JH, Ku K, Beak SH, Lee CS, Kim S, Park EC, Park D, Lee JJ, Byeon CW, Lee J, Maeng JS, Kim SJ, Kim SI, Kim BT, Kim MJ, Kim HG. 2020a. Comparative Analysis of Primer-Probe Sets for RT-qPCR of COVID-19 Causative Virus (SARS-CoV-2). *ACS Infectious Diseases* 6: 2513–2523. DOI: https://doi.org/10.1021/acsinfecdis.0c00464, PMID: 32786273

Kawecki C, Lenting PJ, Denis CV. 2017. von Willebrand factor and inflammation. *Clinical Hemorheology and Microcirculation* 75: 7–11. DOI: https://doi.org/10.3233/CHM-209007

Kaneko N, Satta S, Komuro Y, Muthukrishnan SD, Kakarla V, Guo L, An J, Elahi F, Kornblum HI, Liebeskind DS, Hinman JD. 2021. Flow-Mediated Susceptibility and Molecular Response of Cerebral Endothelia to SARS-CoV-2 Infection. *Stroke* 52: 260–270. DOI: https://doi.org/10.1161/STROKEAHA.120.032764, PMID: 32161843

Kaushal N, Gupta Y, Goyal M, Khaiboullina SF, Banarwal M, Verma SC. 2020. Mutational Frequencies of SARS-CoV-2 Genome during the Beginning Months of the Outbreak in USA. *Pathogens* 9: E565. DOI: https://doi.org/10.3390/pathogens9070565, PMID: 32668692

Kawecki C, Lenting PJ, Denis CV. 2017. von Willebrand factor and inflammation. *Journal of Thrombosis and Haemostasis* 15: 1285–1294. DOI: https://doi.org/10.1111/jth.13696, PMID: 28671350

Kevil CG, Okayama N, Trocha SD, Kalogeris TJ, Coe LL, Specian RD, Davis CP, Alexander JS. 1998. Expression of zona occuludens and adherens junctional proteins in human venous and arterial endothelial cells: role of occuludin in endothelial solute barriers. *Microcirculation* 5: 197–210. PMID: 9789260.

Kim D, Lee MJ, Kim JW, Kim VN, Chang H. 2020. The Architecture of SARS-CoV-2 Transcriptome. *Cell* 181: 914–921. DOI: https://doi.org/10.1016/j.cell.2020.04.011, PMID: 32330414

Kluger MS, Clark PR, Tellides G, Gerke V, Pofer J. 2013. Claudin-5 controls intercellular barriers of human microvascular but not human umbilical vein endothelial cells. *Arteriosclerosis, Thrombosis, and Vascular Biology* 33: 489–500. DOI: https://doi.org/10.1160/ATVBAHA.112.300893, PMID: 23288152

Kutner RH, Zhang XY, Reiser J. 2009. Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. *Nature Protocols* 4: 495–505. DOI: https://doi.org/10.1038/nprot.2009.22, PMID: 19300443

Latifi N, Sarathchandra P, Taylor PM, Antoniw J, Brand N, Yakoub MH. 2006. Characterization of molecules mediating cell-cell communication in human cardiac valve interstitial cells. *Cell Biochemistry and Biophysics* 45: 255–264. DOI: https://doi.org/10.1385/BB:45:3:255, PMID: 16845172

Lee MH, Perl DP, Nair G, Li W, Maric D, Murray H, Dodd SJ, Koretsky AP, Watts JA, Cheung V, Masliah E, Horkayne-Szakaly I, Jones R, Stram MN, Moncur J, Hefti M, Folktherd RD, Nath A. 2021. Microvascular Injury in

Rauti, Shahoha, et al. *eLife* 2021;10:e69314. DOI: https://doi.org/10.7554/eLife.69314

19 of 22
the Brains of Patients with Covid-19. *The New England Journal of Medicine* **384**: 481–483. DOI: https://doi.org/10.1056/NEJMc2033369, PMID: 33378608

Lengfeld JE, Lutz SE, Smith JR, Diaconu C, Scott C, Kofman SB, Choi C, Walsh CM, Raine CS, Agalliu I, Agalliu D. 2017. Endothelial Wnt/β-catenin signaling reduces immune cell infiltration in multiple sclerosis. *PNAS* **114**: E1168–E1177. DOI: https://doi.org/10.1073/pnas.1609951114, PMID: 28137846

Liao Y, Li X, Mou T, Zhou X, Li D, Wang L, Zhang Y, Dong X, Zheng H, Guo L, Liang Y, Jiang G, Fan S, Xu X, Xie Z, Chen H, Liu L, Li Q. 2020a. Distinct infection process of SARS-CoV-2 in human bronchial epithelial cell lines. *Journal of Medical Virology* **92**: 2830–2838. DOI: https://doi.org/10.1002/jmv.26200, PMID: 32558946

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J, Cheng L, Li J, Wang X, Wang F, Liu L, Amit I, Zhang S, Zhang Z. 2020b. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. *Nature Medicine* **26**: 842–844. DOI: https://doi.org/10.1038/s41591-020-0901-9, PMID: 32398877

Libby P, Lüscher T. 2020. COVID-19 is, in the end, an endothelial disease. *European Heart Journal* **41**: 3038–3044. DOI: https://doi.org/10.1093/eurheartj/ehaa623, PMID: 32882706

Lin T, Luo W, Li Z, Zhang L, Zheng X, Mai L, Yang W, Guan G, Su Z, Liu P, Li Z, Xie Y. 2020. Rhamnocitrin extracted from Nervilia fordii inhibited vascular endothelial activation via mr-185-STIM-1/OCCE/NFATc3. *Phytomedicine: International Journal of Phytotherapy and Phytopharmacology* **79**: 153350. DOI: https://doi.org/10.1016/j.phymed.2020.153350, PMID: 33002827

Maciel RAP, Cunha RS, Busato V, Franco CRC, Gregório PC, Dolenqa CJR, Nakao LS, Massy ZA, Bouiller A, Pecoiots-Filho R, Stinghen AEM. 2018. Uremia Impacts VE-Cadherin and ZO-1 Expression in Human Endothelial Cell-to-Cell Junctions. *Toxins* **10**: E404. DOI: https://doi.org/10.3390/toxins10040404, PMID: 30301260

Matarease A, Gambardella J, Sardu C, Santulli G. 2020. miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19. *Biomedicines* **8**: 462. DOI: https://doi.org/10.3390/biomedicines8110462, PMID: 33143053

Medina-Leyte DJ, Domínguez-Pérez M, Mercado I, Villareal-Molina MT, Jacobo-Albavera L. 2020. Use of Vascular Cell Adhesion Molecule-1 (VCAM-1) as a Biomarker of COVID-19: A Systematic Review. *Applied Sciences* **10**: 938. DOI: https://doi.org/10.3390/app10030938

Miller B, Silverstein A, Flores M, Cao K, Kumagai H, Mehta HH, Yen K, Kim SJ, Cohen P. 2021. Host mitochondrial transcriptome response to SARS-CoV-2 in multiple cell models and clinical samples. *Scientific Reports* **11**: 3. DOI: https://doi.org/10.1038/s41598-020-79552-z

Murakami M, Nguyen LT, Zuang ZW, Zhang ZW, Moodie WR, Gorbunova EE, Mackow ER. 2020. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells. *Cell Reports* **31**: 107774. DOI: https://doi.org/10.1016/j.celrep.2020.107774, PMID: 32531208

Nagel FP, Altevogt P, Tschumperlin DJ, Schüppel D, Luginbühl P, Lüscher T. 2020. COVID-19 is, in the end, an endothelial disease. *European Heart Journal* **41**: 3038–3044. DOI: https://doi.org/10.1093/eurheartj/ehaa623, PMID: 32882706

Nagel FP, Altevogt P, Tschumperlin DJ, Schüppel D, Luginbühl P, Lüscher T. 2020. COVID-19 is, in the end, an endothelial disease. *European Heart Journal* **41**: 3038–3044. DOI: https://doi.org/10.1093/eurheartj/ehaa623, PMID: 32882706

Nagel MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. 2020. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. *Atherosclerosis* **314**: 58–62. DOI: https://doi.org/10.1016/j.atherosclerosis.2020.10.014, PMID: 33161318

Nakato R, Wada Y, Nakaki R, Nagaie G, Katou Y, Tsutsumi S, Nakajima N, Fukuhara H, Iguchi A, Kohro T, Kanki Y, Saito Y, Kobayashi M, Ishii-Taguchi A, Osato N, Tatsuno K, Kamio A, Hayashi-Takanaka Y, Wada H, Ohta S, et al. 2019. Comprehensive epigenome characterization reveals diverse transcriptional regulation across human vascular endothelial cells. *Epigenetics & Chromatin* **12**: e0319-0. DOI: https://doi.org/10.1186/s13072-019-0319-0

Nascimento Conde J, Schutt WR, Gorbunova EE, Mackow ER. 2020. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses. *MBio* **11**: e03185-20. DOI: https://doi.org/10.1128/mBio.03185-20, PMID: 33310781

Orologas-Stavrou N, Politou M, Rousakis P, Kostopoulos IV, Ntanasis-Stathopoulos I, Jahaj E, Nțegle MP, Nguyen LT, Zhuang ZW, Zhang ZW, Moodie WR, Gorbunova EE, Mackow ER. 2020. Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells. *Cell Reports* **31**: 107774. DOI: https://doi.org/10.1016/j.celrep.2020.10.07774, PMID: 32531208

Peruzzi B, Bencini S, Capone M, Mazzoni A, Maggi L, Salvati L, Vanni A, Razzini C, Nozilli C, Moretti A, Pogglesi L, Pifferi F, Peris A, Bartoloni A, Vannucci AM, Liotta F, Caporale R, Cosmi L, Annunziato F. 2020. Quantitative and qualitative alterations of circulating myeloid cells and plasmacytoid DC in SARS-CoV-2 infection. *Immunology* **161**: 345–353. DOI: https://doi.org/10.1111/imn.13254, PMID: 32870529

Pinto MT, Ferreira Melo FU, Malta TM, Rodrigues ES, Plaça JR, Silva WA, Panepucci RA, Covas DT, de Oliveira Rodrigues C, Kashima S. 2018. Endothelial cells from different anatomical origin have distinct responses during SNAIL/TGF-β2-mediated endothelial-mesenchymal transition. *American Journal of Translational Research* **10**: 4065–4081 PMID: 30662651.

Pober JS, Sessa WC. 2007. Evolving functions of endothelial cells in inflammation. *Nature Reviews. Immunology* **7**: 803–815. DOI: https://doi.org/10.1038/ni2171, PMID: 17893694
Polus A, Kiec-Wilk B, Hartwich J, Balwierz A, Stachura J, Dydych G, Laidler P, Zagajewski J, Langman T, Schmitz-Goralczyk R, Wertz K, Riss G, Keijer J, Dembinska-Kiec A. 2006. The chemotactic activity of beta-carotene in endothelial cell progenitors and human umbilical vein endothelial cells: A microarray analysis. *Experimental and Clinical Cardiology* 11: 117–122. PMID: 18651047.

Pons S, Fodil S, Azoayul E, Zafrañii L. 2020. The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. *Critical Care* 24: 353. DOI: https://doi.org/10.1186/s13054-020-03062-7, PMID: 32546188

Potus F, Mai V, Lebret M, Malenfant S, Breton-Gagnon E, Lajoie AC, Boucherat O, Bonnet S, Provencher S. 2020. Novel insights on the pulmonary vascular consequences of COVID-19. *American Journal of Physiology. Lung Cellular and Molecular Physiology* 319: L277–L288. DOI: https://doi.org/10.1152/ajplung.00195.2020, PMID: 32551862

Procko E. 2020. The Sequence of Human ACE2 Is Suboptimal for Binding the S Spike Protein of SARS Coronavirus 2. bioRxiv. DOI: https://doi.org/10.1101/2020.03.16.994236, PMID: 32511321

Pum A, Ennemoser M, Adage T, Kungl AJ. 2021. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm. *Biomolecules* 11: 91. DOI: https://doi.org/10.3390/biom11010091, PMID: 33445810

Rietveld IM, Lifering WM, Je Cessie S, Bos MHA, Rosendaal FR, Reitsma PH, Cannegieter SC. 2019. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. *Journal of Thrombosis and Haemostasis* 17: 99–109. DOI: https://doi.org/10.1111/j.1444-0115.2009.02749.x, PMID: 30471183

Romano M, Ruggiero A, Squeglia F, Maga G, Berisio R. 2020. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. *Cells* 9: 1267. DOI: https://doi.org/10.3390/cells9051267, PMID: 32443810

Sandig M, Korvemaker ML, Ionescu CV, Negrou E, Rogers KA. 1999. Transendothelial migration of monocytes in rat aorta: distribution of F-actin, alpha-catnin, LFA-1, and PECAM-1. *Biotechnic & Histochemistry* 74: 276–293. DOI: https://doi.org/10.3109/1052029990934666, PMID: 10768807

Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. *Nature Methods* 9: 676–682. DOI: https://doi.org/10.1038/nmeth.2019, PMID: 22743772

Siddiqi HK, Libby P, Ridker PM. 2020. COVID-19 and vascular disease. *EbioMedicine* 58: 102966. DOI: https://doi.org/10.1016/j.ebiom.2020.102966, PMID: 32829782

Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, Hickman JJ. 2015. TEER measurement techniques for in vitro models of vasculogenesis and angiogenesis. *Machinery: RNA Synthesis, Proofreading and Final Capping*. Cells 9: 1267. DOI: https://doi.org/10.3390/cells9051267, PMID: 32443810

Teuwen LA, Geldhof V, Pasut A, Carmeliet P. 2020. COVID-19: the vasculature unleashed. *Nature Reviews. Immunology* 20: 389–391. DOI: https://doi.org/10.1038/s41577-020-0343-0, PMID: 32439870

Vallvé B, Villet D, Feige JJ. 2001. vitro models of vasculogenesis and angiogenesis. *Laboratory Investigation; a Journal of Technical Methods and Pathology* 81: 439–452. DOI: https://doi.org/10.1038/labinvest.3780252, PMID: 11304563

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Rutschitzka F, Moch H. 2020. Endothelial cell infection and endotheliitis in COVID-19. *Lancet* 395: 1417–1418. DOI: https://doi.org/10.1016/S0140-6736(20)30937-5, PMID: 32354467

Vestweber D, Winderlich M, Cagna G, Nottebaum AF. 2009. Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. *Trends in Cell Biology* 19: 8–15. DOI: https://doi.org/10.1016/j.tcb.2008.10.001, PMID: 19010680

Wang L, Chang ET, Simmons JT, Garcia JGN, Dudek SM. 2011. FTY720-induced human pulmonary endothelial barrier enhancement is mediated by c-Abl. *The European Respiratory Journal* 38: 78–88. DOI: https://doi.org/10.1183/09031936.00047810, PMID: 21071472

Wang J, Jiang M, Chen X, Montaner LJ. 2020a. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. *Journal of Leukocyte Biology* 108: 17–41. DOI: https://doi.org/10.1177/0742580520272R, PMID: 32534467

Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. 2020b. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* 323: 1843–1844. DOI: https://doi.org/10.1001/jama.2020.3786, PMID: 32159775

Wazny V, Siau A, Wu KK, Cheung C. 2020. Vascular underpinning of COVID-19. *Open Biology* 10: 200208. DOI: https://doi.org/10.1093/oxb1/oxab010, PMID: 32847471

Wessells H, Sullivan CJ, Tsubota Y, Engel KL, Kim B, Olson NE, Thorner D, Chitaley K. 2009. Transcriptional profiling of human cavernosal endothelial cells reveals distinctive cell adhesion phenotype and role for claudin 11 in vascular barrier function. *Physiological Genomics* 39: 100–108. DOI: https://doi.org/10.1152/physiogenomics.90354.2008, PMID: 19622796

Wu H, Yao Q, Lumsden A, Chen C. 2004. Characterization of two populations of human coronary artery endothelial cells(1). The *Journal of Surgical Research* 118: 38–44. DOI: https://doi.org/10.1016/j.jss.2004.01.009, PMID: 15093715

Wu JC, Yan HC, Chen WH, Wang CJ, Chi YC, Kao WY. 2008. JNK signaling pathway is required for bFGF-mediated surface cadherin downregulation on HUVEC. *Experimental Cell Research* 314: 421–429. DOI: https://doi.org/10.1016/j.yexcr.2007.10.002, PMID: 18164704
Wu M, Zhang J-D, Tang R-N, Crowley SD, Liu H, Lv L-L, Ma K-L, Liu B-C. 2017. Elevated PTH induces endothelial-to-chondrogenic transition in aortic endothelial cells. American Journal of Physiology. Renal Physiology 312: F436–F444. DOI: https://doi.org/10.1152/ajprenal.00210.2016, PMID: 27582099

Xiao J, Zhang B, Su Z, Liu Y, Shelite TR, Chang Q, Wang P, Bukreyev A, Soong L, Jin Y, Ksiazek T, Gaitas A, Rossi SL, Zhou J, Laposata M, Saito TB, Gong B. 2020. EPAC Regulates von Willebrand Factor Secretion from Endothelial Cells in a PI3K/ENOS-Dependent Manner during Inflammation. [bioRxiv]. DOI: https://doi.org/10.1101/2020.09.04.282806, PMID: 32908983

Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, Derclaye S, Vincent SP, Soumillion P, Alsteens D. 2020. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nature Communications 11: 4541. DOI: https://doi.org/10.1038/s41467-020-18319-6, PMID: 32917884

Yuan L, Le Bras A, Sacharidou A, Itagaki K, Zhan Y, Kondo M, Carman CV, Davis GE, Aird WC, Oettgen P. 2012. ETS-related gene (ERG) controls endothelial cell permeability via transcriptional regulation of the claudin 5 (CLDN5) gene. The Journal of Biological Chemistry 287: 6582–6591. DOI: https://doi.org/10.1074/jbc.M111.300236, PMID: 22235125

Zebda N, Tian Y, Tian X, Gawlak G, Higginbotham K, Reynolds AB, Birukova AA, Birukov KG. 2013. Interaction of p190RhoGAP with C-terminal domain of p120-catenin modulates endothelial cytoskeleton and permeability. The Journal of Biological Chemistry 288: 18290–18299. DOI: https://doi.org/10.1074/jbc.M112.342757, PMID: 23653363